With this prospective randomized clinical trial, we aim to investigate if the use of prophylactic PMMF on the pharyngeal closure for reinforcement in TL patients under high risk for PCF because of low (SMM), can reduce the risk of PCF to a level of…
ID
Source
Brief title
Condition
- Head and neck therapeutic procedures
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
In a randomized clinical trial the addition of PMMF as onlay for reinforcement
in low SMM patients will be investigated. Patients who are planned for TL
without PMMC for reconstruction of the mucosal defect will be asked to
participate in this study. After informed consent SMM will be measured using
routinely performed CT or MRI of the head and neck. Patients with low SMM will
be randomized between PMMF reconstruction at the time of TL or not. Incidence
of PCF will be scored for the three groups: patients with low SMM with PMMF as
onlay for reinforcement, patients with low SMM without PMMF and patients
without low SMM. It is hypothesized that the use of PMMF can reduce the PCF
rate to a level similar to TL patients without low SMM.
Skeletal muscle mass measurement
SMM is measured on pre-treatment CT or MRI scans of the head and neck area at
the level of C3 using a previously published method. Whenever possible, CT
imaging was used instead of MRI. In brief, the first slide at the level of C3
when scrolling from caudal to cranial direction to show both transverse
processes and the entire vertebral arc is selected for segmentation of skeletal
muscle (SM) tissue. For CT imaging, skeletal mass (SM) area is defined as the
pixel area within a radiodensity between -29 and +150 Hounsfield Units (HU),
which is specific for SM tissue. For MRI, SM tissue is carefully segmented and
any intramuscular fatty tissue is manually excluded. Segmentation of SM tissue
was manually performed using in house or commercially available software
package SliceOmatic (Tomovision, Canada). An example of SM tissue segmentation
at the level of C3 is shown in Figure 1. After a learning period, the
measurement of SMM requires 5 to 10 minutes per CT scan, and up to 15 minutes
per MRI scan.
From SM area at C3, SM area at the level of L3 is predicted using the
previously published Formula 1. The SM area at L3 is then normalized for height
to calculate the lumbar skeletal muscle index (lumbar SMI), as shown in Formula
2. 12 Low SMM is defined as a lumbar SMI lower than 43.2cm2/m2. This recently
published cut off value was established in a separate cohort of head and neck
cancer patients.
Formula 1:
CSA at L3 (cm2)=27.304+1.363*CSA at C3 (cm2)-0.671*Age (years)+0.640 *Weight
(kg)+26.442 *Sex (Sex=1 for female, 2 for male)
Formula 2:
Lumbar SMI (cm2/m2)=CSA at L3 /length (m2)
In patients who underwent FDG-PET/CT as part of the diagnostic work-up, as a
control of SMM measurement at the level of C3, SMM will also be measured at the
level of L3, which is the most commonly used method in medical literature as a
control of SMM measurement at the level of C3. However, the use of a SMM
measurement at the level of C3 is highly preferable, because of national and
international differences in performing whole body FDG-PET/CT imaging in HNSCC.
Secondary outcome
All patients are asked to fill out the questionnaires, but performing function
tests will be dependent on the ability in each participating center. At least
in 3 centers the following function tests will be performed: patients with low
SMM will be tested for shoulder and neck disability, swallowing function and
voice quality. Also patients with secondary (for PCF treatment) PM flap will
undergo these tests. Sub analysis will be performed to investigate if there is
a difference in morbidity between prophylactic and secondary PM flap harvest.
Shoulder and neck function
Questionnaires (secondary study parameter)
The shoulder disability questionnaire (SDQ) is a validated pain-related
disability questionnaire including 16 items that describe common conditions
that may induce symptoms in patients with disorders of the shoulder. All items
refer to the preceding 24 hours. Options are *yes*, *no* and *not applicable*.
The *not applicable* category should be used when the condition referred to has
not occurred during the preceding 24 hours. A final score is calculated
dividing the number of *yes* scored items by the total number of items
applicable. And then multiplying the score by 100 results in a final score that
ranges between 0 (no disability) and 100 (all applicable items scored *yes*).
The higher the score, the greater the impairment was. All patients are asked to
fill out the questionnaires for both the left and the right shoulder
separately.
Shoulder function will also be measured with the Shoulder Pain and
Disability Index Dutch Language Version (SPADI-DLV). This questionnaire
consists of 13 items, 5 related to pain and 5 related to function.
Pain of the shoulder is rated on a visual analogue scale (VAS: 0-100
millimeter). Patients are asked to indicate the mean shoulder pain intensity
over the past week.
Patients are also asked if they had experienced stiffness of the shoulder
during the previous week (yes or no).
The Neck Disability Index (NDI) is a questionnaire that captures elements of
neck disability such as pain, work, and headache. The NDI consist of a 10 six
point Likert scale question.
Function tests (part of the main study; performance dependent on the ability in
each participating center)
Active range of motion (AROM) of the shoulder is examined using an inclinometer
according to a standardized protocol. Forward flexion and abduction are
measured in the range of 0-180*. The mean of two sequential measurements is
used for further analysis. To examine endorotation and exorotation an
inclinometer cannot be used because these are combined movements. These will be
measured with a goniometer.
The AROM with the lateroflexion, rotation, extension and flexion of the neck,
is examined using the digital inclinometer.
Swallowing function
Questionnaires (secondary study parameters)
The Dysphagia Severity Scale (DSS) and Dysphagia Quality of Life Scale (DQOL)
are both for laryngetomized patients,non-validated, but rather simple scales to
measure the degree of dysphagia. Patients can indicate on the specific
visualized analogue scale in how they asses swallowing today. The scale ranges
from *not being able to swallow* to * being able to swallow normally* in case
of the DSS. With the DQOL patients will answer to what extend their daily lives
are influenced by the swallowing disorder on the current day. Answers range
from *maximum burden or limitation* to * normal/no burden or limitation.'
The swallowing function in patients after laryngectomy will be measured using
the self-reported patient questionnaire, the Swallow Outcomes After
Laryngectomy (SOAL).[58] This questionnaire is not yet validated for the Dutch
language, but particularly specific for patients with a laryngectomy. This
questionnaire consists of 17 questions about swallowing status and
difficulties. Patients can answer *no*, *a little* or *a lot*. Since we want to
validate the SOAL-questionnaire for the Dutch language, we will use the M.D.
Anderson Dysphagia Inventory (MDADI) to compare the validity. MDADI is a
self-administered questionnaire for head and neck cancer patients and validated
for the Dutch language. The impact of dysphagia on the quality of life is
evaluated. Patients can answer if they *strongly agree*, *agree*, *have no
opinion*, *disagree* or *strongly disagree* with statements about the
swallowing ability and views of the patient.
The Functional Oral Intake Scale (FOIS) for dysphagia is the only investigator
reported outcome questionnaire. It is a standardized 7 point scale to measure
the level of intake (1= complete tube feeding-nothing oral, 7= all intake via
oral rout without restrictions ). The questionnaire is not specifically
designed for laryngectomees, but still gives a good descriptive measure of the
patients.
Function tests (side study; performance dependent on the ability in each
participating center)
To demonstrate the type and extent of an swallowing disorder the Video
Fluoroscopic Swallow Study (VFSS) is the most common used exam. The VFSS gives
detailed information about the swallowing dysfunction. Recommendations
regarding by what method the patient should be nourished can be given
afterwards. This radiographic procedure will be performed only 6 months after
TL.
Voice quality
Questionnaires (secondary study parameter)
Using the Voice Handicap Index (VHI), the psychosocial consequences of voice
disorder will be quantified. This questionnaire is validated for the Dutch
language and based on statements made by people to describe their voice quality
and the effect of their voice on their daily lives. TL - patients can answer if
they *never* , *almost never*, *sometimes*, *almost always* or *always*
experience these statements themselves. The VHI-30 will be used.
Quality index (side study; performance dependent on the ability in each
participating center)
The investigator reported outcome measure will be the Acoustic Voice Quality
Index (AVQI). This index is developed in 2010 and is one of the first indexes
to measure the quality of the voice with a sustained vocalized and continuous
speech. AVQI is a multi-parameter model in which the outcomes of six acoustic
parameters are measured and combined into one objective measure of the severity
of voice quality. Voices of patients will be recorded postoperatively dependent
on the ability in each participating center.
Quality of Life (secondary study parameters)
The following questionnaires will be used to measure QoL: EORTC QLQ-C30,
EORTC-QLQ-H&N35, specific for head and neck cancer patients and EQ-5D-5L. The
EORTC-QLQ is designed to be cancer-specific, multidimensional in structure,
appropriate for self-administration and applicable across a range of cultural
settings. Dutch reference values are available. The EQ-5D is a standardized
instrument can be used as a quantitative measure of health outcome that can be
used in a wide range of health conditions and treatments, and reflects the
patient*s own judgement. Questionnaires are asked to fill out before and 6
months after laryngectomy. The EQ-5D-5L will be filled out 3 months after TL
also.
Patients* experience (secondary study parameter)
Patients* experience with the needed rehabilitation of shoulder and neck
function, swallowing function and voice quality related to provided information
and therapy will be explored by qualitative research with semi-structures
interviews based on a interview guide with a topic list. Questions will focus
on patients* experience with the provided information, content of the needed
therapy related to physical functioning like neck and shoulder problems,
swallowing and speech quality. Semi-structured interviews will be analyzed by
two researchers using thematic descriptive analyses. Data coding will be done
by open, axial and selective coding and will be supported by the software
package NVivo.
Cost-effectiven
Background summary
In The Netherlands about 160 patients per year undergo total laryngectomy (TL).
Postoperative complications including the occurrence of a pharyngocutaneous
fistula (PCF) are common and difficult to treat. In a Dutch national study with
324 TL patients the PCF rate was 25.9%. PCF may require additional surgery,
prolongs feeding tube dependency, delays or interrupts oral feeding and voice
rehabilitation and increases hospital stay and costs. PCF carries a high risk
of postoperative infections, wound breakdown and subsequent damage to nearby
tissue and structures, including potential carotid artery blowout. PCF may also
cause delay of postoperative (chemo)radiotherapy, thus jeopardizing optimal
oncological treatment. Surgical closure of PCF, is indicated in half of the
cases. Most often a myocutaneous pectoralis major flap (PMMC) is used to
restore the mucosal defect. This surgery is associated with complications
because of the poor tissue quality due to infection and saliva exposure.
A surgical strategy to minimize PCF development following TL is the transfer of
a pectoralis major myofascial flap (PMMF) to the neck as onlay for
reinforcement of the pharyngeal closure. Systemic reviews show that a
prophylactic PMMF reduces the risk of PCF in TL patients significantly. The use
of prophylactic PMMF on the pharyngeal closure for reinforcement is recommended
for patients with high risk for PCF.
Low skeletal muscle mass (SMM) has been related to negative outcomes in a
variety of tumour types and treatments. In oncological patients, SMM is most
commonly assessed on abdominal computed tomography (CT) imaging at the level of
the third lumbar vertebra (L3). Abdominal CT imaging is not routinely performed
in head and neck cancer patients, and is often only available in a preselected
patient group with advanced disease and high risk features for distant
metastasis. Recently, a novel SMM assessment method at the level of the third
cervical vertebra (C3) was published. Imaging at the level of C3 is almost
always available in TL patients, allowing for the routine assessment of SMM
without any extra burden for the patient or healthcare-related costs.
Two studies reported that preoperative low SMM is a significant predictor of
PCF in patients undergoing TL. Recently we reported on another series of 235
patients undergoing TL either with or without reconstruction of the pharynx
with PMMC/PMMF and SMM measured using CT or MRI scans at the level of C3. Low
SMM was observed in 109 patients (46.4%). Patients with low SMM had more
frequently PCF than patients with normal SMM (34.9% versus 20.6%, p=0.019) and
prolonged hospital stay (median 17 versus 14 days, p<0.001). In multivariate
logistic regression analysis low SMM remained significant predictors of PCF (OR
1.950). After exclusion of the patients who received a reconstruction of the
pharynx with PMMCor PMMF from the database, the PCF rate in patients with low
skeletal muscle mass was 31.0%.
Two systematic reviews of Paleri et al and Sayles et al describe a reduced risk
of fistula formation in patients who underwent primary salvage surgery with the
prophylactic PMMC or PMMF flap. The incidence of PCF was reduced (47/156 to
11/114), giving a relative risk of 0.32.
Study objective
With this prospective randomized clinical trial, we aim to investigate if the
use of prophylactic PMMF on the pharyngeal closure for reinforcement in TL
patients under high risk for PCF because of low (SMM), can reduce the risk of
PCF to a level of TL patients without low SMM. We hypothesize that in patients
with low SMM the use PMMF as onlay for reinforcement can reduce the PCF rate
after TL from 31.0% to 9.9%.
Study design
In a multicenter randomized clinical trial patients who are planned for TL
without PMMC flap for reconstruction of the mucosal defect will be asked to
participate in this study. SMM is measured on pre-treatment CT or MRI scans at
the level of C3 using a previously published method. One hundred twenty-eight
patients with low SMM will be randomized between prophylactic PMMF flap at the
time of TL or not. Incidence of PCF will be scored for the following groups:
patients with low SMM with PMMF flap as onlay for reinforcement, patients with
low SMM without PMMF and patients without low SMM. In patients with or without
low SMM and who unexpectedly needed the PMMC for reconstruction of the pharynx
PCF incidence will also be scored following the *intention-to-treat*
analysis. In low SMM patients shoulder morbidity, swallowing function and
perception of dysphagia and the voice quality with their psychosocial
consequences will be investigated by questionnaires and shoulder function test
before and 6 months after TL. Patients* experience will be explored by
qualitative research with semi-structures interviews. Quality of life will be
measured using EORTC questionnaires. A cost-effectiveness analysis will be
performed.
Intervention
PMMF flap in TL patients with low SMM randomized for intervention arm
Study burden and risks
Burdens: Patients in the intervention arm will receive PMMF with potential
shoulder morbidity. Patients with low SMM will be asked to complete
questionnaires before and 6 months after TL. The EQ-5D-5L will be filled out 3
months after TL also. Shoulder function tests,voice recording and
videofluoroscopic swallowing study (VFSS) will be performed dependent on the
ability in each participating study. The shoulder function test will be
performed before and 6 months after TL and is part of the main study. VFSS and
voice recording only 6 months after TL. Radiation dose during VFSS will be <
1.5mSv, which is a lot less than a routinely performed CT thorax (4 mSv).It is
estimated that it takes 50 minutes to fill out all questionnaires at one time
point. Function tests will take 45 minutes. The questionnaires and function
tests will be conducted during a routine consultation. Additional operation
time for harvesting the PM flap will take 30 minutes. It is expected that the
use of PMMF will result in less and limited (duration and extent) PCF, shorter
hospital stay, less delay in adjuvant treatment, lower costs and improved
quality of life. PMMC for fistula closure is probably associated with more
morbidity than prophylactic PMMF. For TL patients, this study may serve as a
basis for a reduction of PCF, which is a difficult problem to manage and is
associated with severe complications and reduction of quality of life.
Prevention of PCF is essential in the management of TL patients.
Heidelberglaan 100
Utrecht 3584 CX
NL
Heidelberglaan 100
Utrecht 3584 CX
NL
Listed location countries
Age
Inclusion criteria
• Planned for TL
• Eighteen years of age or older, and able to exercise their free will.
• Sufficient understanding of the Dutch language to give informed consent.
Exclusion criteria
- Planned for TL with pharyngectomy and reconstruction of the pharynx with
PMMC.
- Planned TL with pharyngectomy and reconstruction with jejunal flap or gastric
pull-up.
- Planned TL after treatment with chemoradiotherapy (cisplatin/carboplatin) for
a previously diagnosed head and neck carcinoma
- Major (FDG-PET/)CT or MRI artefacts, impeding accurate muscle tissue
identification on
imaging.
- Interval between TL and imaging > 2 months.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
In other registers
Register | ID |
---|---|
CCMO | NL72319.041.20 |